Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13.30M | $184.0M | 8.33% | -30.5K | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.09M | $84.0M | 3.82% | -- | 2026-03-31 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 5.44M | $75.0M | 3.40% | +1.38M | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.49M | $62.0M | 2.81% | -- | 2026-03-31 |
| Invesco Ltd. | 4.45M | $61.0M | 2.79% | +1.34M | 2026-03-31 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.86M | $53.0M | 2.42% | +1.69M | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 3.64M | $50.0M | 2.28% | +124.2K | 2026-03-31 |
| LORD, ABBETT & CO. LLC | 3.54M | $49.0M | 2.21% | +455.3K | 2026-03-31 |
| GOLDMAN SACHS GROUP INC | 3.24M | $44.0M | 2.03% | +339.8K | 2026-03-31 |
| STATE STREET CORP | 3.23M | $44.0M | 2.02% | +45.6K | 2026-03-31 |
